Cartesian Therapeutics (RNAC) has provided an announcement.
Cartesian Therapeutics, Inc. regularly shares updates on its business through slide presentations at various conferences, with the latest one now available in a report. Additionally, the company’s stockholders recently approved a conversion of Series A Preferred Stock into common shares, which took effect on April 8, 2024, resulting in over 17 million common shares currently outstanding. This move is part of the company’s ongoing efforts to streamline its capital structure and potentially enhance shareholder value.
For an in-depth examination of RNAC stock, go to TipRanks’ Stock Analysis page.
